EzeRx Health Tech is a medtech startup based in India, with sources naming Kolkata and Bhubaneswar, that builds a hand-held non-invasive screening device for early signs of chronic conditions.

This Startup Deep Dive explains what EzeRx Health Tech does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

EzeRx Health Tech in Brief

• What it is: EzeRx Health Tech is an Indian Non-invasive diagnostic device company.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• EzeRx's IoT-enabled device AJO screens for anaemia, liver and lung-related problems and blood glucose levels without drawing blood.
• The device is hand-held and aimed at early diagnosis of chronic diseases.
• 2020: Raised a Rs 1.75 crore seed round from angel investors (reported).
• Funding: Not disclosed in public sources reviewed.

EzeRx Health Tech Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is EzeRx Health Tech?

EzeRx Health Tech operates in the Non-invasive diagnostic device space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to EzeRx Health Tech.

• EzeRx's IoT-enabled device AJO screens for anaemia, liver and lung-related problems and blood glucose levels without drawing blood.
• The device is hand-held and aimed at early diagnosis of chronic diseases.

The Origin Story of EzeRx Health Tech

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Partha, Chaitali Roy, Sudip Roy Chowdhury.
• The company was founded in 2018 by Partha with Chaitali Roy and Sudip Roy Chowdhury.
• Headquarters: reports differ, with early coverage saying Kolkata and later reports saying Bhubaneswar.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Non-invasive diagnostic device sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• 2020: Raised a Rs 1.75 crore seed round from angel investors (reported).
• 2022: Undisclosed seed funding from Mankind Pharma promoters, including Sheetal Arora (reported).
• February 2024: Signed an MoU with IMGENEX India for low-cost AI-powered screening tools.

EzeRx Health Tech Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• 2020: Rs 1.75 crore seed from angels (reported).
• 2022: undisclosed seed from Mankind Pharma promoters (reported).
• Earlier grants from DST's NIDHI Prayas and BIRAC's BIG programmes.

How Does EzeRx Health Tech Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• The company sells a diagnostic screening device; the 2022 funding was meant to expand sales.

The Numbers: EzeRx Health Tech Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• Audited revenue, profit and loss figures for EzeRx Health Tech were not available in the public sources reviewed.
• Readers can check the company’s filings with the Registrar of Companies for the latest financial statements.

Market Opportunity for EzeRx Health Tech

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Planned expansion across India, Africa and Southeast Asia.

Technology and Product at EzeRx Health Tech

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• IoT-enabled, non-invasive hand-held device named AJO.

Team and Culture at EzeRx Health Tech

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Partha, Chaitali Roy and Sudip Roy Chowdhury are the co-founders.

EzeRx Health Tech Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

• Direct competitors of EzeRx Health Tech vary by product line; a verified rival comparison was not available from public sources.
• What to compare: Product readiness, pricing, customer base, funding runway and regulatory standing.

Risks and Challenges for EzeRx Health Tech

• No newer public updates than the 2024 partnership were found, so current status is unclear.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.
• Data privacy risk: health records are sensitive, and breaches or misuse can bring legal and reputational harm.
• Thin margins: low-ticket services and heavy customer-acquisition spend can keep unit economics weak.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

EzeRx Health Tech Growth Outlook: What to Watch

• The 2022 funding was meant for global certifications, R&D and sales expansion in India, Africa and Southeast Asia.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether EzeRx Health Tech can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where EzeRx Health Tech Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for EzeRx Health Tech

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for EzeRx Health Tech.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from EzeRx Health Tech

Studying a company in the Non-invasive diagnostic device space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about EzeRx Health Tech.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate EzeRx Health Tech as a Startup

• Customer clarity: Can EzeRx Health Tech name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

EzeRx Health Tech is part of India’s growing Non-invasive diagnostic device ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

EzeRx Health Tech FAQs: Frequently Asked Questions

What is EzeRx Health Tech?

EzeRx Health Tech is a medtech startup based in India, with sources naming Kolkata and Bhubaneswar, that builds a hand-held non-invasive screening device for early signs of chronic conditions. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded EzeRx Health Tech?

EzeRx Health Tech was founded by Partha, Chaitali Roy, Sudip Roy Chowdhury, and the company reports a founding year of 2018.

How much funding has EzeRx Health Tech raised?

No reliable total funding figure is disclosed in the public sources reviewed. Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does EzeRx Health Tech make money?

EzeRx Health Tech earns revenue from its Non-invasive diagnostic device products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of EzeRx Health Tech?

Competitors of EzeRx Health Tech depend on the specific product line. A verified comparison was not available, so see the evaluation checklist above.

What are the main risks for EzeRx Health Tech?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Bellatrix Aerospace — Bengaluru maker of water-fuelled satellite thrusters | Pandorum Technologies — Pandorum raised $18M for bioengineered cornea therapy. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.